BioScience Health Innovations Inc. reported significant financial growth for the fiscal year ending December 31, 2025, with revenues reaching $5.69 million, a 208% increase from $1.84 million in 2024. The company also achieved a net income of $642,090, compared to a net income of $87,000 in the previous year, resulting in an improved net margin of 11.3%, up from 4.7%. This growth was attributed to expanded revenue channels, including direct-to-consumer sales and increased wholesale partnerships, as well as the introduction of new products leveraging the company's proprietary MODS Max™ delivery system.
In terms of operational developments, BioScience Health Innovations has made substantial investments in its infrastructure, including upgrading its consumer-facing website and migrating its accounting systems to Oracle NetSuite. These enhancements are aimed at supporting anticipated growth and improving operational efficiency. The company also reported a significant increase in general and administrative expenses, which rose to $2.21 million from $1.15 million in 2024, reflecting the costs associated with scaling operations and expanding product offerings.
As of December 31, 2025, the company had 10,979,058 shares of common stock outstanding, held by 53 stockholders. The stock trades on the OTC Pink Market under the symbol "NOTR," with a market price consistently at $4.00 throughout 2025. The company has not paid any cash dividends since its inception and does not foresee declaring any in the near future. Additionally, the company is currently pursuing a Regulation A offering to raise $1.5 million, with plans for a major exchange uplist and an additional capital raise of $5 million to $7.5 million to fund further growth.
Looking ahead, BioScience Health Innovations is focused on expanding its product lines, particularly in testosterone optimization and NAD+ restoration, leveraging its MODS Max delivery technology. The company is also exploring pharmacy partnerships to enhance distribution and is preparing to release a book titled "The Living Chip" to educate consumers and healthcare practitioners about its health optimization approach. Management believes these initiatives will position the company for continued growth and market disruption in the health and wellness sector.
About BioScience Health Innovations, Inc.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.